ICU抗菌藥物用藥劑量不足風(fēng)險研討新_第1頁
ICU抗菌藥物用藥劑量不足風(fēng)險研討新_第2頁
ICU抗菌藥物用藥劑量不足風(fēng)險研討新_第3頁
ICU抗菌藥物用藥劑量不足風(fēng)險研討新_第4頁
ICU抗菌藥物用藥劑量不足風(fēng)險研討新_第5頁
已閱讀5頁,還剩40頁未讀, 繼續(xù)免費閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認(rèn)領(lǐng)

文檔簡介

1、ICU抗菌藥物用藥劑量不足風(fēng)險研討新 VPA 1.2g/d,3d后,VPA 39.91 更改至1.6g/d,7d后,VPA 19.32 ( VAP 達(dá)標(biāo) 濃度 50-100) VAN 1.0g,q12h,2d后,VAN 2.37 (VAN 達(dá)標(biāo)濃度10,甚至更高)臨床常用的給藥劑量 哌拉西林他唑巴坦哌拉西林他唑巴坦 (4.5g/支)支)臨床常用的給藥劑量 美羅培南(美羅培南(0.5g/支)支) However, when a subject is exposed to a standard dose of an antibacterial in daily practice, the pK/p

2、D ratio achieved may be lower than expected as a consequence of the patients clinical condition and the characteristics of the involved pathogen This may be considered as underdosing, the result of which will be a therapeutic failure. In critically ill patients, there are a number of reasons for an

3、inadequate pK/pD ratio of antimicrobials at the site of infection and that should be considered in case of poor clinical outcome or therapeutic failure (table III).1. 給藥劑量不足按照實際體重計算用藥劑量 (actual bodyweight)氨基糖苷類、糖肽類、兩性霉素氨基糖苷類、糖肽類、兩性霉素B、達(dá)托霉素、達(dá)托霉素按照標(biāo)準(zhǔn)體重估算給藥劑量 (standardized bodyweight)內(nèi)酰胺類、替加環(huán)素、棘白菌素、大環(huán)內(nèi)

4、脂、喹諾酮類內(nèi)酰胺類、替加環(huán)素、棘白菌素、大環(huán)內(nèi)脂、喹諾酮類宜進行劑量調(diào)整人群包括宜進行劑量調(diào)整人群包括1.Overweight2.親脂性藥物 actual bodyweight3.親水性藥物 ideal bodyweight2.感染局部濃度不足感染局部濃度不足原因分析原因分析1.血供減少2.細(xì)胞膜通過/進入障礙3.分布容積增加/膠體滲透壓減低4.蛋白結(jié)合率高的藥物分布障礙5.屏障作用(CNS)3.清除率增加清除率增加美羅培南比阿培南美羅培南比阿培南With dialysis, without previous liver transplantation/resection,with dial

5、ysis, with previous liver transplantation/resectionwithout dialysis,without previous liver transplantation/resectionwithout dialysis, with previous liver transplantation/resectionConclusion Dialysis increased the CI of linezolid by 3.5 L/h, corresponding to a mean increase of 23%. In patients after

6、liver transplantation/resection, linezolid CI was reduced by 60% relative to patients without prior liver transplantation/resection.No correlation could be established between anidulafungin exposureand disease severity or plasma protein concentrations inthis group of critically ill patients. In this

7、 population, we observed a lower anidulafungin exposure than in the general patient population.In patients infected with a susceptible Candida albicans orglabrata strain with a MIC well below the breakpoint, no problemsare to be expected in the case of a lower exposure. However, in patients with less-susceptible Candida albicans or glabrata strains,a lower exposure can be a problem. If theMICis high

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

最新文檔

評論

0/150

提交評論